A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital

Ravi Kumar P; Tarun Arora; Rudhra Prabhakar Kadali; Rakhmaji D Chandane; Umesh Devappa Suranagi

doi:10.5455/njppp.2022.12.114172202129112021

2023, Vol: 13, Issue: 5

13/5Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Natl J Physiol Pharm Pharmacol. 2022; 12(6): 806-812

doi: 10.5455/njppp.2022.12.114172202129112021

A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital

Ravi Kumar P, Tarun Arora, Rudhra Prabhakar Kadali, Rakhmaji D Chandane, Umesh Devappa Suranagi.

Abstract
Background: Polytherapy and comorbidities are a significant component of drug prescriptions in type 2 Diabetes mellitus (T2DM) patients. Irrational prescriptions and increased cost and number of drug therapies in T2DM put a considerable burden on patients as well as health authorities. Drug utilization studies are a very important tool in the evaluation of such prescriptions for logistical planning and medical audit of a health care setup.

Aims and Objectives: To determine the drug utilization patterns of Antihyperglycaemic agents in diabetic patients attending medicine outpatient department and to assess average cost per prescription and to assess the economic implication.

Materials and Methods: A prospective observational drug audit was carried out between January 2017 to June 2018 to determine drug utilization patterns of antihyperglycemic and other agents in T2DM patients attending medicine outpatient department of Konaseema Institute of Medical Science General Hospital, Amalapuram. The data were assessed using the World Health Organization indicators for drug utilization and analyzed using mean percentage and Chi-square tests. Value of P < 0.05 was taken as significant.

Results: Metformin had highest Defined Daily Dose of 0.77 and was the most common drug prescribed both as monotherapy (14%) and in combination therapy with glimepiride (42.5%). Amlodipine (15.5%) was the most common non-diabetic drug prescribed in our patients. Average number of drugs per prescription was 3.05, while average number of antihyperglycemic agents per prescription was 1.81. Average cost per prescription was under rupees 50 in 30% of patients and all drugs were prescribed by their brand names.

Conclusion: Metformin should be available in sufficient quantities in health care system for T2DM patients and drugs should be prescribed by generic names to reduce cost of drug treatment.

Key words: Type 2 Diabetes Mellitus; Drug Utilization Studies; Metformin; Defined Daily Dose; Prescriptions; Cost

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Ravi Kumar P Articles by Tarun Arora Articles by Rudhra Prabhakar Kadali Articles by Rakhmaji D Chandane Articles by Umesh Devappa Suranagi
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

P RK, Arora T, Kadali RP, Chandane RD, Suranagi UD. A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2022; 12(6): 806-812. doi:10.5455/njppp.2022.12.114172202129112021

Web Style

P RK, Arora T, Kadali RP, Chandane RD, Suranagi UD. A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital. https://www.njppp.com/?mno=10705 [Access: May 03, 2023]. doi:10.5455/njppp.2022.12.114172202129112021

AMA (American Medical Association) Style

P RK, Arora T, Kadali RP, Chandane RD, Suranagi UD. A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2022; 12(6): 806-812. doi:10.5455/njppp.2022.12.114172202129112021

Vancouver/ICMJE Style

P RK, Arora T, Kadali RP, Chandane RD, Suranagi UD. A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital. Natl J Physiol Pharm Pharmacol. (2022), [cited May 03, 2023]; 12(6): 806-812. doi:10.5455/njppp.2022.12.114172202129112021

Harvard Style

P, R. K., Arora, . T., Kadali, . R. P., Chandane, . R. D. & Suranagi, . U. D. (2022) A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital. Natl J Physiol Pharm Pharmacol, 12 (6), 806-812. doi:10.5455/njppp.2022.12.114172202129112021

Turabian Style

P, Ravi Kumar, Tarun Arora, Rudhra Prabhakar Kadali, Rakhmaji D Chandane, and Umesh Devappa Suranagi. 2022. A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 12 (6), 806-812. doi:10.5455/njppp.2022.12.114172202129112021

Chicago Style

P, Ravi Kumar, Tarun Arora, Rudhra Prabhakar Kadali, Rakhmaji D Chandane, and Umesh Devappa Suranagi. "A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 806-812. doi:10.5455/njppp.2022.12.114172202129112021

MLA (The Modern Language Association) Style

P, Ravi Kumar, Tarun Arora, Rudhra Prabhakar Kadali, Rakhmaji D Chandane, and Umesh Devappa Suranagi. "A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 12.6 (2022), 806-812. Print. doi:10.5455/njppp.2022.12.114172202129112021

APA (American Psychological Association) Style

P, R. K., Arora, . T., Kadali, . R. P., Chandane, . R. D. & Suranagi, . U. D. (2022) A drug utilization study of antihyperglycemic agents in diabetes mellitus cases of a South Indian tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 12 (6), 806-812. doi:10.5455/njppp.2022.12.114172202129112021

Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information



Copyright © 2023 National Journal of Physiology, Pharmacy and Pharmacology All Rights Reserved. Subject to change without notice from or liability to National Journal of Physiology, Pharmacy and Pharmacology. For best results, please use Internet Explorer or Google Chrome	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272

Contact Information

How to cite this article